AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05765084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum/pemetrexed based chemotherapy
Description: On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
Study NCT05600725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: novel atrial pacing approach
Description: See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
Study NCT05600725 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham pacing approach
Description: A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
Study NCT05975502 — intervention group
Intervention type: OTHER
Intervention: Epidemiological study
Description: Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
Study NCT05335668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Testing
Description: Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
Study NCT05335668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Testing
Description: Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
Study NCT06632340 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TUR-BT
Description: Transurethral resection of bladder tumor
Study NCT06008288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: 800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
Study NCT05188729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 Part 1
Description: LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
Study NCT05188729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-315 Part 2
Description: VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
Study NCT05347121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: difficult airway
Description: ultrasonography of airway
Study NCT05180019 — intervention group
Intervention type: DEVICE
Intervention: SMD ( Self Monitoring Device)
Description: Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oral oseltamivir 75mg BD for 5/7
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Inhaled zanamivir 10mg BD for 5/7
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir
Description: Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0
Study NCT05038501 — intervention group
Intervention type: OTHER
Intervention: To study comorbidities in patients undergoing Oncosurgeries
Description: In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
Study NCT04021121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LZD
Description: LZD 1200 mg daily
Study NCT04021121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose RIF
Description: RIF 35 mg/kg/day
Study NCT04021121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose RIF
Description: RIF 10 mg/kg/day
Study NCT04021121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose RIF
Description: RIF 10 mg/kg/day
Study NCT04878484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCRT-ESO-A2
Description: TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1.
Study NCT04711928 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity and sedentary behaviour
Description: Athletes with a high physical activity and a low or high sedentary time
Study NCT04881032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
Description: Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
Study NCT04881032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 60 Gy in 6 weeks
Study NCT04881032 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: radiotherapy
Description: 60 Gy in 6 weeks
Study NCT04881032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days .
Study NCT04881032 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Temozolomide
Description: Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days .
Study NCT04796623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
Study NCT04796623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
Study NCT04699110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
Study NCT04699110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Control group will receive adenosine (100 to 400 mcg)
Study NCT05268575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: performing endoscopy
Description: Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
Study NCT05941325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
Study NCT05941325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral molnupiravir 800mg BD for 5/7
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: Intravenous peramivir 600mg once only
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laninamivir
Description: Inhaled laninamivir 40mg once only
Study NCT05027399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nursing teleconsultation for lifestyle changes
Description: Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
Study NCT05762835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual family-centered rounds (FCR)
Description: Parents will be given the option to join FCR virtually or in-person; this intervention is changing the behavior of how providers deliver healthcare and how parents engage in their child's care.~The NICU team members will use a computer with a speaker and pan-tilt-zoom camera, mounted on a stand with wheels to launch telehealth connections using the secure application called ExtendedCare. From within this telehealth connection, a NICU team member will send an electronic message (e.g. via text or email) to the subscribed parent(s) and wait for the parent to join the visit to establish a secure videoconference. The message to the parent includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. FCR will then proceed in usual fashion with the NICU team members and - if in attendance - parent(s).
Study NCT04313959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
Study NCT04313959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% + Dexamethasone
Description: Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
Study NCT04695340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Psyllium is given to patients
Study NCT06277635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarin is randomly assigned to the participants for 12 weeks during study.
Study NCT06277635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is randomly assigned to the participants for 12 weeks during study.
Study NCT05536024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of glioma grading and molecular subtype
Description: Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
Study NCT05365672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIC
Description: Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
Study NCT05365672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: No application of the investigational medicinal product MIC
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Baloxavir
Description: Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Favipiravir
Description: Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
Study NCT05648448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir and Baloxavir
Description: favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0
Study NCT04903457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT04903457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor learning
Description: Sequential finger tapping task training is applied to stroke patients.
Study NCT04903457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor learning
Description: Sequential finger tapping task training is applied to stroke patients.
Study NCT06347029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Urine sampling
Study NCT06342427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DESTINEX
Description: A panel of microRNA, whose expression level is tested in serum samples.
Study NCT05508906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-1250
Description: OP-1250 is a small molecule and a CERAN being developed for the treatment of patients with advanced or metastatic ER+ and HER2- breast cancer.
Study NCT05508906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: All subjects in Treatment Group 1 will receive OP-1250 in combination with ribociclib.
Study NCT05508906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: All subjects in Treatment Group 2 will receive OP-1250 in combination with alpelisib.
Study NCT05508906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: All subjects in Treatment Group 3 will receive OP-1250 in combination with everolimus.
Study NCT06392672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group: Group to which the clinical pharmacist makes recommendations
Description: The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
Study NCT06024772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultiparametric Magnetic Resonance Imaging
Description: Undergo mp-MRI
Study NCT06024772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Given IV
Study NCT06024772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasound
Description: Undergo transrectal mp-US
Study NCT06024772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsies
Study NCT04978259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
Study NCT05458167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hedia Diabetes Assistant bolus calculator with a physical activity module
Description: Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
Study NCT05458167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hedia Diabetes Assistant bolus calculator with a physical activity module
Description: Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
Study NCT04303312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzydamine Hydrochloride
Description: Patients will rinse by mouth three times daily for 20 days
Study NCT04303312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Solcoseryl and pumpkin seed oil
Description: Patients will receive by mouth three times daily for 20 days
Study NCT04342624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Cinnamon supplement
Study NCT04342624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06162338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY-M001 Injection
Description: With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
Study NCT05799937 — intervention group
Intervention type: PROCEDURE
Intervention: Non Surgical Root Canal Treatment
Description: After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
Study NCT05156463 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PAI Tool and Exercise Coaching
Description: Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
Study NCT05790213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide Oral Product
Description: Apalutamide 240 mg by mouth daily for a total of 6-months.
Study NCT05790213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).
Study NCT05790213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Therapy
Description: Focal therapy to be completed within 8- to 12-weeks of the initiation of apalutamide but after the completion of the 8-week mpMRI to allow for it to be used in FT planning.
Study NCT06215651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab lenvatinib
Description: ±TACE/HAIC
Study NCT05199805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based pain management
Description: The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
Study NCT05386251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT/OST
Description: See Arm description.
Study NCT05386251 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peer Support
Description: See Arm description
Study NCT06382285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continues peripheral block
Description: ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
Study NCT06382285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continues peripheral block
Description: ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
Study NCT05091866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05091866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05091866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Progesterone
Description: Given SC